http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 12 Jun 2026 08:10:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html <p><em>Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP)</em></p> <p><em>A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers.</em></p> <p>SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. <a href="https://www.globenewswire.com/Tracker?data=DAF4ICzr92dlu5TgvS_gdahH51kOlZU3eEXQeeHJZONaA97a6_7kaJtjvJ2-0wQWdMZryMV07pASdB9xaknFSxFsTjp-rcdZHAlhcxa1l1VOm2QfQGYdOyfzhwOUHAFopwE6OI0X_42uV45lASgnFA==" rel="nofollow" target="_blank"><u>GT Biopharma, Inc. (Nasdaq: GTBP)</u></a> has now advanced three TriKE® candidates http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html Mon, 08 Jun 2026 09:01:00 -0400 FATE GTBP GTBP IBRX IOVA NKTX http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html <p><em>Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP)</em></p> <p><em>A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers.</em></p> <p>SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. <a href="https://www.globenewswire.com/Tracker?data=DAF4ICzr92dlu5TgvS_gdahH51kOlZU3eEXQeeHJZONaA97a6_7kaJtjvJ2-0wQWdMZryMV07pASdB9xaknFSxFsTjp-rcdZHAlhcxa1l1VOm2QfQGYdOyfzhwOUHAFopwE6OI0X_42uV45lASgnFA==" rel="nofollow" target="_blank"><u>GT Biopharma, Inc. (Nasdaq: GTBP)</u></a> has now advanced three TriKE® candidates http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html Mon, 08 Jun 2026 09:01:00 -0400 FATE GTBP GTBP IBRX IOVA NKTX http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html <p><em>Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP)</em></p> <p><em>A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers.</em></p> <p>SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. <a href="https://www.globenewswire.com/Tracker?data=DAF4ICzr92dlu5TgvS_gdahH51kOlZU3eEXQeeHJZONaA97a6_7kaJtjvJ2-0wQWdMZryMV07pASdB9xaknFSxFsTjp-rcdZHAlhcxa1l1VOm2QfQGYdOyfzhwOUHAFopwE6OI0X_42uV45lASgnFA==" rel="nofollow" target="_blank"><u>GT Biopharma, Inc. (Nasdaq: GTBP)</u></a> has now advanced three TriKE® candidates http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html Mon, 08 Jun 2026 09:01:00 -0400 FATE GTBP GTBP IBRX IOVA NKTX http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html <p><em>Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP)</em></p> <p><em>A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers.</em></p> <p>SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. <a href="https://www.globenewswire.com/Tracker?data=DAF4ICzr92dlu5TgvS_gdahH51kOlZU3eEXQeeHJZONaA97a6_7kaJtjvJ2-0wQWdMZryMV07pASdB9xaknFSxFsTjp-rcdZHAlhcxa1l1VOm2QfQGYdOyfzhwOUHAFopwE6OI0X_42uV45lASgnFA==" rel="nofollow" target="_blank"><u>GT Biopharma, Inc. (Nasdaq: GTBP)</u></a> has now advanced three TriKE® candidates http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html Mon, 08 Jun 2026 09:01:00 -0400 FATE GTBP GTBP IBRX IOVA NKTX http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html <p><em>Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP)</em></p> <p><em>A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers.</em></p> <p>SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. <a href="https://www.globenewswire.com/Tracker?data=DAF4ICzr92dlu5TgvS_gdahH51kOlZU3eEXQeeHJZONaA97a6_7kaJtjvJ2-0wQWdMZryMV07pASdB9xaknFSxFsTjp-rcdZHAlhcxa1l1VOm2QfQGYdOyfzhwOUHAFopwE6OI0X_42uV45lASgnFA==" rel="nofollow" target="_blank"><u>GT Biopharma, Inc. (Nasdaq: GTBP)</u></a> has now advanced three TriKE® candidates http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html Mon, 08 Jun 2026 09:01:00 -0400 FATE GTBP GTBP IBRX IOVA NKTX http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html <p><em>Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP)</em></p> <p><em>A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers.</em></p> <p>SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. <a href="https://www.globenewswire.com/Tracker?data=DAF4ICzr92dlu5TgvS_gdahH51kOlZU3eEXQeeHJZONaA97a6_7kaJtjvJ2-0wQWdMZryMV07pASdB9xaknFSxFsTjp-rcdZHAlhcxa1l1VOm2QfQGYdOyfzhwOUHAFopwE6OI0X_42uV45lASgnFA==" rel="nofollow" target="_blank"><u>GT Biopharma, Inc. (Nasdaq: GTBP)</u></a> has now advanced three TriKE® candidates http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html Mon, 08 Jun 2026 09:01:00 -0400 FATE GTBP GTBP IBRX IOVA NKTX http://www.streetinsider.com/Globe+Newswire/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html <p><em>Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP)</em></p> <p><em>A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers.</em></p> <p>SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. <a href="https://www.globenewswire.com/Tracker?data=DAF4ICzr92dlu5TgvS_gdahH51kOlZU3eEXQeeHJZONaA97a6_7kaJtjvJ2-0wQWdMZryMV07pASdB9xaknFSxFsTjp-rcdZHAlhcxa1l1VOm2QfQGYdOyfzhwOUHAFopwE6OI0X_42uV45lASgnFA==" rel="nofollow" target="_blank"><u>GT Biopharma, Inc. (Nasdaq: GTBP)</u></a> has now advanced three TriKE® candidates http://www.streetinsider.com/Globe+Newswire/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html Mon, 08 Jun 2026 09:01:00 -0400 FATE GTBP GTBP IBRX IOVA NKTX http://www.streetinsider.com/Globe+Newswire/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html <p><em>Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP)</em></p> <p><em>A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers.</em></p> <p>SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. <a href="https://www.globenewswire.com/Tracker?data=DAF4ICzr92dlu5TgvS_gdahH51kOlZU3eEXQeeHJZONaA97a6_7kaJtjvJ2-0wQWdMZryMV07pASdB9xaknFSxFsTjp-rcdZHAlhcxa1l1VOm2QfQGYdOyfzhwOUHAFopwE6OI0X_42uV45lASgnFA==" rel="nofollow" target="_blank"><u>GT Biopharma, Inc. (Nasdaq: GTBP)</u></a> has now advanced three TriKE® candidates http://www.streetinsider.com/Globe+Newswire/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html Mon, 08 Jun 2026 09:01:00 -0400 FATE GTBP GTBP IBRX IOVA NKTX http://www.streetinsider.com/Globe+Newswire/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html <p><em>Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP)</em></p> <p><em>A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers.</em></p> <p>SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. <a href="https://www.globenewswire.com/Tracker?data=DAF4ICzr92dlu5TgvS_gdahH51kOlZU3eEXQeeHJZONaA97a6_7kaJtjvJ2-0wQWdMZryMV07pASdB9xaknFSxFsTjp-rcdZHAlhcxa1l1VOm2QfQGYdOyfzhwOUHAFopwE6OI0X_42uV45lASgnFA==" rel="nofollow" target="_blank"><u>GT Biopharma, Inc. (Nasdaq: GTBP)</u></a> has now advanced three TriKE® candidates http://www.streetinsider.com/Globe+Newswire/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html Mon, 08 Jun 2026 09:01:00 -0400 FATE GTBP GTBP IBRX IOVA NKTX http://www.streetinsider.com/Globe+Newswire/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html <p><em>Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP)</em></p> <p><em>A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers.</em></p> <p>SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. <a href="https://www.globenewswire.com/Tracker?data=DAF4ICzr92dlu5TgvS_gdahH51kOlZU3eEXQeeHJZONaA97a6_7kaJtjvJ2-0wQWdMZryMV07pASdB9xaknFSxFsTjp-rcdZHAlhcxa1l1VOm2QfQGYdOyfzhwOUHAFopwE6OI0X_42uV45lASgnFA==" rel="nofollow" target="_blank"><u>GT Biopharma, Inc. (Nasdaq: GTBP)</u></a> has now advanced three TriKE® candidates http://www.streetinsider.com/Globe+Newswire/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html Mon, 08 Jun 2026 09:01:00 -0400 FATE GTBP GTBP IBRX IOVA NKTX http://www.streetinsider.com/Globe+Newswire/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html <p><em>Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP)</em></p> <p><em>A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers.</em></p> <p>SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. <a href="https://www.globenewswire.com/Tracker?data=DAF4ICzr92dlu5TgvS_gdahH51kOlZU3eEXQeeHJZONaA97a6_7kaJtjvJ2-0wQWdMZryMV07pASdB9xaknFSxFsTjp-rcdZHAlhcxa1l1VOm2QfQGYdOyfzhwOUHAFopwE6OI0X_42uV45lASgnFA==" rel="nofollow" target="_blank"><u>GT Biopharma, Inc. (Nasdaq: GTBP)</u></a> has now advanced three TriKE® candidates http://www.streetinsider.com/Globe+Newswire/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html Mon, 08 Jun 2026 09:01:00 -0400 FATE GTBP GTBP IBRX IOVA NKTX http://www.streetinsider.com/Globe+Newswire/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html <p><em>Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP)</em></p> <p><em>A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers.</em></p> <p>SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. <a href="https://www.globenewswire.com/Tracker?data=DAF4ICzr92dlu5TgvS_gdahH51kOlZU3eEXQeeHJZONaA97a6_7kaJtjvJ2-0wQWdMZryMV07pASdB9xaknFSxFsTjp-rcdZHAlhcxa1l1VOm2QfQGYdOyfzhwOUHAFopwE6OI0X_42uV45lASgnFA==" rel="nofollow" target="_blank"><u>GT Biopharma, Inc. (Nasdaq: GTBP)</u></a> has now advanced three TriKE® candidates http://www.streetinsider.com/Globe+Newswire/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%27s+TriKE+Bet/26615093.html Mon, 08 Jun 2026 09:01:00 -0400 FATE GTBP GTBP IBRX IOVA NKTX http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%26apos%3Bs+TriKE+Bet/26615099.html <p><em>Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP)</em></p> <p><em>A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers.</em></p> <p>SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. <a target="_blank" href="https://www.globenewswire.com/Tracker?data=DAF4ICzr92dlu5TgvS_gdahH51kOlZU3eEXQeeHJZONaA97a6_7kaJtjvJ2-0wQWdMZryMV07pASdB9xaknFSxFsTjp-rcdZHAlhcxa1l1VOm2QfQGYdOyfzhwOUHAFopwE6OI0X_42uV45lASgnFA==" rel="nofollow" target="_blank">GT Biopharma, Inc. (Nasdaq: GTBP)</a> has now advanced three TriKE® http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%26apos%3Bs+TriKE+Bet/26615099.html Mon, 08 Jun 2026 09:01:00 -0400 A.28110669 FATE GTBP IBRX IOVA NKTX O.00035925 O.06574973 O.07103920 O.25176488 O.38360402 O.48401414 http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%26apos%3Bs+TriKE+Bet/26615099.html <p><em>Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP)</em></p> <p><em>A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers.</em></p> <p>SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. <a target="_blank" href="https://www.globenewswire.com/Tracker?data=DAF4ICzr92dlu5TgvS_gdahH51kOlZU3eEXQeeHJZONaA97a6_7kaJtjvJ2-0wQWdMZryMV07pASdB9xaknFSxFsTjp-rcdZHAlhcxa1l1VOm2QfQGYdOyfzhwOUHAFopwE6OI0X_42uV45lASgnFA==" rel="nofollow" target="_blank">GT Biopharma, Inc. (Nasdaq: GTBP)</a> has now advanced three TriKE® http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%26apos%3Bs+TriKE+Bet/26615099.html Mon, 08 Jun 2026 09:01:00 -0400 A.28110669 FATE GTBP IBRX IOVA NKTX O.00035925 O.06574973 O.07103920 O.25176488 O.38360402 O.48401414 http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%26apos%3Bs+TriKE+Bet/26615099.html <p><em>Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP)</em></p> <p><em>A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers.</em></p> <p>SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. <a target="_blank" href="https://www.globenewswire.com/Tracker?data=DAF4ICzr92dlu5TgvS_gdahH51kOlZU3eEXQeeHJZONaA97a6_7kaJtjvJ2-0wQWdMZryMV07pASdB9xaknFSxFsTjp-rcdZHAlhcxa1l1VOm2QfQGYdOyfzhwOUHAFopwE6OI0X_42uV45lASgnFA==" rel="nofollow" target="_blank">GT Biopharma, Inc. (Nasdaq: GTBP)</a> has now advanced three TriKE® http://www.streetinsider.com/Press+Releases/Three+Cancer+Drugs+Have+Reached+the+Clinic%3A+Inside+GT+Biopharma%26apos%3Bs+TriKE+Bet/26615099.html Mon, 08 Jun 2026 09:01:00 -0400 A.28110669 FATE GTBP IBRX IOVA NKTX O.00035925 O.06574973 O.07103920 O.25176488 O.38360402 O.48401414